Short answer · Medically reviewed summary · Last updated: 2026-05-08
Anti-NMDA receptor encephalitis is a rare, immune-mediated condition with an estimated annual incidence of approximately 1.5 per million people, though true prevalence remains difficult to determine due to significant underdiagnosis. While once considered ultra-rare, increased clinical awareness has revealed that Anti-NMDA receptor encephalitis is one of the most common causes of autoimmune encephalitis worldwide. What is the prevalence and incidence of Anti-NMDA receptor encephalitis? Data regarding Anti-NMDA receptor encephalitis is evolving rapidly.
What is the prevalence of Anti-NMDA Receptor Encephalitis?
Prevalence of Anti-NMDA Receptor Encephalitis: how many people are affected worldwide, differences by sex and region, with sources.
Anti-NMDA receptor encephalitis is a rare, immune-mediated condition with an estimated annual incidence of approximately 1.5 per million people, though true prevalence remains difficult to determine due to significant underdiagnosis. While once considered ultra-rare, increased clinical awareness has revealed that Anti-NMDA receptor encephalitis is one of the most common causes of autoimmune encephalitis worldwide.
What is the prevalence and incidence of Anti-NMDA receptor encephalitis?
Data regarding Anti-NMDA receptor encephalitis is evolving rapidly. While the annual incidence is estimated at 1.5 per million, the prevalence is higher among specific subgroups. Because many patients are initially misdiagnosed with psychiatric disorders or viral encephalitis, current epidemiological figures are likely conservative. At DiseaseMaps.org, 76 people have joined our community to share their experiences with Anti-NMDA receptor encephalitis, providing a vital real-world perspective that complements clinical data.
Who is most at risk for Anti-NMDA receptor encephalitis?
Epidemiological patterns for Anti-NMDA receptor encephalitis show distinct trends regarding age and gender:
- Gender Distribution: Females are affected more frequently than males, with a ratio of approximately 4:1, largely due to the association with ovarian teratomas.
- Age of Onset: While it can affect all ages, the median age of onset is approximately 21 years; however, it is frequently seen in children and adolescents.
- Geographic Variation: No specific ethnic or geographic "hotspots" have been definitively identified, suggesting Anti-NMDA receptor encephalitis occurs globally across all populations.
Why is accurate data on Anti-NMDA receptor encephalitis challenging to obtain?
The primary challenge in mapping the prevalence of Anti-NMDA receptor encephalitis is the complexity of the diagnostic process. Symptoms often mimic primary psychiatric conditions, leading to delays in neurological testing. Furthermore, the specialized antibody testing required to confirm Anti-NMDA receptor encephalitis is not universally accessible in all healthcare settings, leading to cases that go uncounted in official registries.
Next steps
- Consult a neuro-immunologist if you suspect symptoms of Anti-NMDA receptor encephalitis.
- Join our community at DiseaseMaps.org to connect with others who have navigated the diagnostic journey.
- Advocate for early lumbar puncture and serum antibody testing if autoimmune encephalitis is suspected.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- Orphanet (ORPHA:263435) – Anti-N-methyl-D-aspartate receptor encephalitis.
- NIH GARD (Genetic and Rare Diseases Information Center) – Anti-NMDA receptor encephalitis overview.
- Dalmau, J., et al. (2008). "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies." The Lancet Neurology.
- The Encephalitis Society – Global patient support and clinical information resources.
